DiaSorin (OTCMKTS:DSRLF) Shares Gap Up – Here’s Why

DiaSorin S.p.A. (OTCMKTS:DSRLF)’s stock price gapped up prior to trading on Monday. The stock had previously closed at $84.12, but opened at $92.00. DiaSorin shares last traded at $92.00, with a volume of 226 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on DSRLF shares. BNP Paribas Exane lowered DiaSorin from a “neutral” rating to an “underperform” rating in a report on Tuesday, July 7th. UBS Group downgraded DiaSorin from a “hold” rating to a “sell” rating in a research note on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of DiaSorin in a report on Tuesday, August 4th. Finally, Zacks Research upgraded DiaSorin from a “strong sell” rating to a “hold” rating in a research note on Friday, October 2nd. Two equities research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Strong Sell”.

DiaSorin Price Performance

The stock’s fifty day simple moving average is $86.11 and its 200-day simple moving average is $79.42.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italian company specializing in in vitro diagnostics, with a focus on immunodiagnostics and molecular diagnostics. Its products are used by hospitals, clinical laboratories and healthcare providers to support the detection, diagnosis and monitoring of a range of diseases and medical conditions.

The company’s portfolio includes automated immunoassay systems, reagents and diagnostic tests marketed under the LIAISON family, as well as molecular diagnostic platforms and assays.